Medicamen Biotech Ltd Financials
Company Logo

Medicamen Biotech Ltd Financial Statement

Medicamen Biotech Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue31.21
Operating Expense27.09
Net Profit2.41
Net Profit Margin7.72
Earning Per Share1.90
EBIDTA4.23
Effective Tax Rate17.68

Medicamen Biotech Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual172.39
Operating Expenses Annual146.42
Operating Profit Annual28.27
Interest Annual4.38
Depreciation6.83
Net Profit Annual13.30
Tax Annual3.59

Medicamen Biotech Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning20.44
Cash Flow from Operations-0.25
Cash Flow from Investing-8.71
Cash Flow from Financing3.14
Cash Flow at the End14.62

Medicamen Biotech Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)17.14
PBIT Margin (%)13.08
PBT Margin (%)10.77
Net PROFIT Margin (%)7.72
Return On Networth / Equity (%)6.60
Return On Networth /Employed (%)9.76
Return On Assets (%)5.79
Total Debt / Equity (X)0.14
Asset Turnover Ratio (%)0.75

Medicamen Biotech Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual91.10
Total Current Assets Annual152.37
Non Current Assets Annual141.84
Total Shareholders Funds Annual209.21
Total Assets Annual294.21

Medicamen Biotech Ltd Earning Calls

EPS (INR)

Expected

1.90

Reported

1.47

Surprise

-22.63%

Dec 2024

EPS beaten by -22.63%

Sep 2024

EPS beaten by -15.75%

Jun 2024

EPS beaten by -38.26%

FAQS on Medicamen Biotech Ltd Financials

As of Jun 1, 2025, Medicamen Biotech Ltd has a market capitalization of 612.46 Cr. Value Research classifies it as a Small-Cap company.

Yes, Medicamen Biotech Ltd is with a debt-to-equity ratio of 0.13.

In FY 2024 , Medicamen Biotech Ltd recorded a total revenue of approximately 151.46 Cr marking a significant milestone in the company's financial performance.

Medicamen Biotech Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.2% and 0.0% annually, respectively..

Medicamen Biotech Ltd's current PE ratio is 64.74.

Medicamen Biotech Ltd's ROCE averaged 8.2% from the FY ending March 2023 to 2025, with a median of 8.9%. It peaked at 9.3% in March 2023, reflecting strong capital efficiency over the period..

Medicamen Biotech Ltd's latest EBIT is Rs. 15.83 Cr, surpassing the average EBIT of Rs. 19.12 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions